Chelsea Baker, PA-C

Sr. Instructor, Medicine-Endocrinology/Metabolism/Diabetes


FacultyPhoto
Medical School
  • PA, University of Colorado Denver School of Medicine (2015)
Graduate School
  • MS, University of Oklahoma Health Sciences Center (2010)
Undergraduate School
  • BS, University of Oklahoma (OK) (2007)
Languages
English
Department
Medicine-Endocrinology/Metabolism/Diabetes

Publications

  • Petri M, Singh I, Baker C, Underkofler C, Rasouli N. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. J Diabetes Complications. 2020 Sep 6;:107733. [Epub ahead of print] PubMed PMID: 32948398
  • Mather KJ, Bebu I, Baker C, Cohen RM, Crandall JP, DeSouza C, Green JB, Kirkman MS, Krause-Steinrauf H, Larkin M, Pettus J, Seaquist ER, Soliman EZ, Schroeder EB, Wexler DJ, Pop-Busui R. Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort. Diabetes Res Clin Pract. 2020 Jul;165:108235. PubMed PMID: 32450102
  • Yusra Azhar, MBBS, Chelsea A Baker, MS, PA-C and Neda Rasouli. Diabetes of Unknown Cause. In: Draznin, B. Atypical diabetes: Pathophysiology, Clinical Presentations, and Treatment Options. American Diabetes Association; 2018.
  • Daniel A. Kelmenson, MD, Kelsey Burr, MD, Yusra Azhar, MBBS, Paul Reynolds, PharmD, BCPS, Chelsea A. Baker, MS, MPAS, and Neda Rasouli, MD. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin. J Investig Med High Impact Case Rep. 2017, 5(2). https://doi.org/10.1177/2324709617712736
  • Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Ther Adv Endocrinol Metab. 2021;12:2042018820980225. PubMed PMID: 33489086
  • Petri M, Singh I, Baker C, Underkofler C, Rasouli N. Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists. J Diabetes Complications. 2021 Feb;35(2):107733. PubMed PMID: 32948398
  • Rella S, Onyiah J, Baker C, Singh V, Her A, Rasouli N. Design and rationale for the SIB trial: a randomized parallel comparison of semaglutide versus placebo on intestinal barrier function in type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2023;14:20420188231207348. PubMed PMID: 37916028

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

UCHealth Diabetes and Endocrinology Clinic - Anschutz Medical Campus
1635 Aurora Ct
6th Floor
Aurora, CO 80045
720-848-2650

Hospital Affiliation
  • University of Colorado Hospital

Specialty Information

Specialties
  • Endocrinology, Diabetes and Metabolism, Board Certification
Clinical Interests
Diabetes management